Our findings provide foundation for further exploring whether the glioma patients with high GOLPH3 expression are more sensitive to anti‐EGFR therapy in clinic and develop possible treatment modalities for gliomas. This evidence concerns the gene GOLPH3 and central nervous system cancer.